Cowen Inc’s Travere Therapeutics TVTX Stock Holding History

Cowen Inc’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-3,000	Closed	-$41K	–	288
2016 Q1	$41K	Buy	+3,000	New	+$45.5K	﹤0.01%	244

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cowen Inc's TVTX Position: Q2 2016 in Review

Cowen Inc sold out of Travere Therapeutics (TVTX) in Q2 2016, closing a stake of 3,000 shares — an estimated $41K sold.

Cowen Inc first reported a position in TVTX in Q1 2016 and held it in 1 quarter. The position peaked at $41K in Q1 2016. 111 funds tracked by Wall St. Rank hold TVTX as of Q2 2016.

Cowen Inc reported no remaining Travere Therapeutics position as of Q2 2016 after selling out during the quarter.
Cowen Inc sold 3,000 Travere Therapeutics shares in Q2 2016, an estimated $41K.
Cowen Inc first reported a position in Travere Therapeutics in Q1 2016 and held it in 1 quarter.
Cowen Inc's Travere Therapeutics position peaked at $41K in Q1 2016.
111 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2016.

Based on Cowen Inc's 13F filing for Q2 2016, filed 10 Aug 2016.